TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05105334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nonablative fractional laser (Fraxel re:store, Solta Medical, Bothell, WA) alone
Description: Nonablative fractional 1550 nm erbium:glass laser. Settings: 40-70 mJ, treatment level 5-7 (14-20% coverage), 8 passes with cold air cooling (Zimmer MedizinSystems, Irvine, CA) set on level 5. To be repeated for a total of 4 sessions at 4-week intervals.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nonablative fractional laser (Fraxel re:store, Solta Medical, Bothell, WA) alone
Description: Nonablative fractional 1550 nm erbium:glass laser. Settings: 40-70 mJ, treatment level 5-7 (14-20% coverage), 8 passes with cold air cooling (Zimmer MedizinSystems, Irvine, CA) set on level 5. To be repeated for a total of 4 sessions at 4-week intervals.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nonablative fractional laser (Fraxel re:store, Solta Medical, Bothell, WA) alternating with microneedling with radiofrequency (Intracel, Perigee Medical, Redwood City, CA)
Description: Nonablative fractional 1550 nm erbium:glass laser. Settings: 40-70 mJ, treatment level 5-7 (14-20% coverage), 8 passes with cold air cooling (Zimmer MedizinSystems, Irvine, CA) set on level 5. This will be alternated with radiofrequency microneedling treatment will include 3 passes each at a depth of 2 mm, 1.5 mm, and 0.8 mm, treatment level 5 (32 w, 50 ms)-7 (40 w, 60 ms), monopolar setting with cold air cooling (Zimmer MedizinSystems, Irvine, CA) set on level 5. To be repeated for a total of 4 sessions (2 of each modality) at 4-week intervals.
Study: NCT04934956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Split-belt walking
Description: These will be used in all experiments and consists of a time period during which the legs move at different speeds (0.5 m/s vs. 1 m/s). The investigators select those speeds since the investigators have observed in our preliminary data and published study (Sombric et al. 2017) that older individuals adapted at these speeds exhibit large deficits at motor switching when transitioning to overground walking. This large reference signal will facilitate the detection of a change in motor switching (Aim 2) following the Intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple transitions between split-belt and tied-belt walking
Description: This intervention consists of multiple short adaptation blocks (i.e., 6 blocks of 200 strides each) interleaved with short de-adaptation blocks (i.e., 5 blocks of 200 strides of tied-belt walking each). It was designed based on several studies showing improvements in adaptation rate in young adults with a similar protocol (Malone et al. 2011; Day et al. 2018; Leech et al. 2018).
Study: NCT05817240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taladegib
Description: 100 mg per tablet, dosed once daily
Study: NCT05909540

Intervention type: PROCEDURE
Intervention: Posterior facet distraction and fusion
Description: With the patient in prone position, cervical traction was only intraoperatively after anesthesia with weights of approximately 5-8 kg during surgery. Monitoring of the spinal cord with motor evoked potential and somatosensory evoked potential were used throughout the surgery. Using a posterior midline incision, the occiput to the C2 spinous process was surgically exposed, separated to the lateral edge of the C1-2 joint, and cut off at the C2 nerve root to expose the C1-2 articular surface Quantitative reduction techniques included the following steps .1) Facet joint release and cage implantation technique 2)Adjusting POCA by cantilever and occipitocervical fixation technique.

Intervention type: PROCEDURE
Intervention: Posterior facet distraction and fusion
Description: With the patient in prone position, cervical traction was only intraoperatively after anesthesia with weights of approximately 5-8 kg during surgery. Monitoring of the spinal cord with motor evoked potential and somatosensory evoked potential were used throughout the surgery. Using a posterior midline incision, the occiput to the C2 spinous process was surgically exposed, separated to the lateral edge of the C1-2 joint, and cut off at the C2 nerve root to expose the C1-2 articular surface Quantitative reduction techniques included the following steps .1) Facet joint release and cage implantation technique 2)Adjusting POCA by cantilever and occipitocervical fixation technique.
Study: NCT05817240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nintedanib
Description: 100 mg per capsule, dosed once daily
Study: NCT04391543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental session
Description: * comprehensive interview~* cognitive tests~* anthropometric measures~* postural balance test~* critical force test~* Astrand-Ryhming test~* self-questionnaire (QLQ-C30, FA12, Brief Cope et Hospital Anxiety and Depression Scale)~* actimetry~* clinical and biological characteristics~* determination of inflammatory markers~* skeletal muscle index
Study: NCT05977608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Reminiscence Intervention
Description: Participants will receive automatic calls three times a week asking their life experiences and personal memories. They can share as much or as little as they would like. They have up to 10 minutes to record their answer and can end the call at any time by hanging up.They will be able to share the stories online with their families if they want.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Reminiscence Intervention
Description: Participants will receive automatic calls three times a week asking their life experiences and personal memories. They can share as much or as little as they would like. They have up to 10 minutes to record their answer and can end the call at any time by hanging up.They will be able to share the stories online with their families if they want.
Study: NCT06142110

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Funcional movement screen
Description: FMS is a biomechanical screening and evaluation method to reveal the limitations and asymmetries on the 7 basic movement patterns, which are the determinants of functional movement quality.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Funcional movement screen
Description: FMS is a biomechanical screening and evaluation method to reveal the limitations and asymmetries on the 7 basic movement patterns, which are the determinants of functional movement quality.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle strength
Description: Respiratory muscle strength was assessed with an additional mouthpiece attached to the portable spirometer as maximum inspiratory pressure and maximum expiratory pressure.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle strength
Description: Respiratory muscle strength was assessed with an additional mouthpiece attached to the portable spirometer as maximum inspiratory pressure and maximum expiratory pressure.
Study: NCT05359887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standardized liquid mixed meal Nutridrink®
Description: Administration of food in controlled situation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standardized liquid mixed meal Nutridrink®
Description: Administration of food in controlled situation
Study: NCT06609655

Intervention type: OTHER
Intervention: no intervention studied, it&#39;s a databank
Description: The AgeTeQ database Arts, health and new information and communication technologies has three objectives.~The first is to preserve the data collected as part of the research projects carried out by the AgeTeQ laboratory.~The second objective of the database is to use the information provided by the recorded data to fuel reflection, test new research hypotheses and thus open up new avenues of research for the Arts, Health and New Information and Communication Technologies research team.~The third objective is to share the AgeTeQ database with the scientific community on a non-commercial basis, to improve access to data on the themes of arts, health and new technologies, and to increase knowledge and enable the development of research in these fields.
Study: NCT06729710

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prism adaptation test
Description: Prism Adapation test for 1 hour in one group, and 4 hours in second group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prism adaptation test
Description: Prism Adapation test for 1 hour in one group, and 4 hours in second group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: other
Description: Surgery based on prism adaptation test of 1 hour in one group and 4 hours in second group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: other
Description: Surgery based on prism adaptation test of 1 hour in one group and 4 hours in second group
Study: NCT06729372

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Deliberate Flawed Performance
Description: Deliberate Flawed Performance during simulation-based training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Error Avoidance Training
Description: Error Avoidance during simulation-based training
Study: NCT06728410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib 13.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg IV
Study: NCT05532735

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANXV
Description: ANXV (Human recombinant Annexin A5 protein)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANXV
Description: ANXV (Human recombinant Annexin A5 protein)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANXV
Description: ANXV (Human recombinant Annexin A5 protein)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANXV
Description: ANXV (Human recombinant Annexin A5 protein)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANXV
Description: ANXV (Human recombinant Annexin A5 protein)
Study: NCT04965675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Eptinezumab will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Eptinezumab will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to eptinezumab will be administered per schedule specified in the arm.
Study: NCT05925257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePRO application and proactive clinical care with nurses.
Description: The investigators defined ePRO intervention as a weekly register of breast cancer patients' symptoms and supportive care needs using the study ePRO App combined with proactive follow-up by nurses guided by predefined clinical algorithms and a weekly cellphone message providing an educational video from a recognised cancer association or health institution. The intervention will be provided for six months with additional three months of post-intervention observation.
Study: NCT05574283

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block and transmuscular quadratus lumborum block
Description: All blocks were performed after securing the airway before the start of surgery.~ESPB group will receive bilateral ultrasound-guided erector spinae plane block using 20 ml of bupivacaine 0.25% with 4 mg dexamethasone for each side.~TQLB group will receive bilateral ultrasound-guided transmuscular quadratus lumborum block using 20 ml of bupivacaine 0.25% with 4 mg dexamethasone for each side

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block and transmuscular quadratus lumborum block
Description: All blocks were performed after securing the airway before the start of surgery.~ESPB group will receive bilateral ultrasound-guided erector spinae plane block using 20 ml of bupivacaine 0.25% with 4 mg dexamethasone for each side.~TQLB group will receive bilateral ultrasound-guided transmuscular quadratus lumborum block using 20 ml of bupivacaine 0.25% with 4 mg dexamethasone for each side
Study: NCT05646563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM8074
Description: NM8074 is an anti-Factor Bb humanized monoclonal antibody that will be administered as an intravenous infusion. Doses will be administered over a treatment period of 13 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM8074
Description: NM8074 is an anti-Factor Bb humanized monoclonal antibody that will be administered as an intravenous infusion. Doses will be administered over a treatment period of 13 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soliris
Description: Complement C5 blocker administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soliris
Description: Complement C5 blocker administered intravenously
Study: NCT05437640

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Protein Redistribution Diet
Description: PD participants will be instructed by a Registered Dietitian to consume 10 grams or less of protein until their evening meal. They will then consume a high protein evening meal to meet their protein needs. They will receive one-on-one education and supportive materials to follow diet plan.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Protein Consistent Diet
Description: PD participants will be instructed by a Registered Dietitian to consume 20-30 grams of protein per meal. They will receive one-on-one education and supportive materials to follow diet plan.
Study: NCT06227546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGC018
Description: Intravenous (IV) Infusion, 2.7 mg/kg on Day 1 of each 28 day cycle
Study: NCT05101928

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: The comparator will be a prednisone taper which is currently the standard care for the uveitis types of focus.
Study: NCT04289428

Intervention type: DIAGNOSTIC_TEST
Intervention: Xpert® HBV DNA fingerstick point of care assay
Description: Xpert® HBV DNA point of care assay from finger-stick whole blood

Intervention type: DIAGNOSTIC_TEST
Intervention: Xpert® HBV DNA fingerstick point of care assay
Description: Xpert® HBV DNA point of care assay from finger-stick whole blood
Study: NCT04403087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimebutine 100 MG
Description: Trimebutine 100mg three times a day
Study: NCT04855006

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaginal Microbiome Transplant
Description: Vaginal Microbiome Transplant is given at least once and up to three times. The transplant is admitted with a syringe

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vaginal Microbiome Transplant Placebo
Description: Vaginal Microbiome Transplant Placebo is given at least once and up to three times. The transplant Placebo is admitted with a syringe

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: Donors have no intervention. This group deliver the transplant to arm 'Vaginal Microbiome Transplant'.
Study: NCT04854876

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-ALA-Phosphate + SFC (5-ALA+SFC)
Description: The food supplement 5-Aminolevulinic acid phosphate and Sodium ferrous citrate (5-ALA-Phosphate + SFC) will be administered orally daily for 28 days. The dose will be in total 3 capsules of 50 mg 5-ALA-Phosphate and 28.68 mg SFC (3.04 mg as Fe) per day, 2 capsules in the morning and 1 capsule in the evening resulting in 150 mg 5-ALA-Phosphate and 86.04 mg SFC ( 9.12 mg as Fe).
Study: NCT05486312

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT-155 smartphone app
Description: The CT-155 study app is designed to provide treatment monitoring and educational components of a full treatment cycle with CT-155. This design allows inferences to be made about the usability and acceptability of CT-155. Eligible participants will be enrolled during an in-person clinic visit on Day 1. Participants will then be directed to access the study app and perform tasks each day for the 49-day engagement period.
Study: NCT05996419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DSB-I
Description: Participant will receive text message every other day during active phase (30days) via ANNIE text messaging app related to the safety behaviors they identified prior to start.
Study: NCT06395025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insoles
Description: Insoles At Day 0, the patient received the insoles and adapted them to his shoes. The patient filled the quality-of-life's questionnaire at Day 0 and the same at Day14. The patient filled a usability's questionnaire at Day14.
Study: NCT05039697

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oxygen
Description: deliver high flow oxygen (10L/min)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen
Description: deliver high flow oxygen (10L/min)
Study: NCT06612164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kefir
Description: Commercial lactose-free kefir (Altinkilic, Turkey) beverage, which is produced from cow milk with 3.1% fat and 7.5% protein content and stored in appropriate conditions, was used in this study. The kefir (intervention) group was provided with 250 mL of plain lactose-free kefir containing at least 107-1010 probiotic bacterial strains (Lactobacillus, Lactic acid, Streptococcus, Acetic acid bacteria sp) and yeasts (Kluyveromyces marxianus, Torulaspora delbrueckii, Saccharomyces cerevisiae, Candida). The participants were asked to consume 250 mL of plain lactose-free kefir daily for 6 weeks. Any particular time was not specified for kefir consumption. Kefir consumption routine of participants was followed up by regular phone calls every week and evaluated by examining their consumption records. Those who consumed less than 85.0% (skipping kefir consumption maximum once a week) of the planned kefir consumption during the study period were excluded from the study.
Study: NCT04035902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Ferric carboxymaltose is administered during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Ferric carboxymaltose is not administered
Study: NCT03357419

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: The subjects will be randomized, at the operation day, to one of two treatment groups:~* group 1: prophylactic antibiotic~* group 2: placebo oral capsule~  * Sealed envelopes, numbered according to the randomization dose, containing the drug or placebo will be prepared in advance and provided to the patient following randomization.~ * Each patient will be given the randomized drug on admission, 30-60 minutes before the surgery, by the nurses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The subjects will be randomized, at the operation day, to one of two treatment groups:~* group 1: prophylactic antibiotic~* group 2: placebo~  * Sealed envelopes, numbered according to the randomization dose, containing the drug or placebo will be prepared in advance and provided to the patient following randomization.~ * Each patient will be given the randomized drug on admission, 30-60 minutes before the surgery, by the nurses.
Study: NCT04530097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: Radiofrequency ablation was performed immediately after enrollment, and melatonin treatment was given for 6 months after 1 week after radiofrequency.
Study: NCT06612892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality games in immersive VR modality
Description: virtual reality involved three characters: a muscular boxer, a superhero, and a rock climber, with patients performing tasks in standing or sitting. Each experience takes 6 minutes, with 5-minute intervals between. Experimenters will instruct users on hand controls and virtual body observation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality show in passive VR modality:
Description: In this modality the patient was asked to have a comfortable seat wearing the head set without holding the controllers , the therapist will play a relaxing show as a nature view or colorful scene as a sort of relaxation and mind distraction for around 20 minutes while asking the patient to perform upper limb muscle ROM exercise in active or active assisted form.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physiotherapy
Description: Includes stretching exercise for upper limb muscles affected by burn, scar tissue release , and splinting technique.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physiotherapy
Description: Includes stretching exercise for upper limb muscles affected by burn, scar tissue release , and splinting technique.
Study: NCT06612775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug CB03-154 5mg group
Description: CB03-154 tablet (5mg/tablet) once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug CB03-154 10mg group
Description: Two CB03-154 tablets (5mg/tablet) once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug CB03-154 20mg group
Description: Four CB03-154 tablets (5mg/tablet) once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Four Placebo tablets once daily.
Study: NCT06612632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: research drug in combination with Toripalimab
Description: research drug in combination with Toripalimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab
Study: NCT06380920

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI Mindful Eating App
Description: The investigators propose on design of an AI Mindful Eating App, to enhance individual's healthy lifestyle with subsequent weight-loss. Based on gut-brain axis, this is anticipated to be achieved by using CBT, in place of medication, to alleviate food addiction and proper nutrition intake during proper metabolic conditions and time, which are coordinated via AI.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outpatient regular follow-up
Description: Outpatient regular follow-up

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Outpatient regular follow-up
Description: Outpatient regular follow-up
Study: NCT06024278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver educational videos for African American caregivers
Description: The intervention will be culturally tailored education videos for African American caregivers receiving hospice services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver educational videos for Puerto Rican caregivers
Description: The intervention will be culturally tailored education videos for Puerto Rican caregivers receiving hospice services.